Radiation Therapy with or without Cisplatin in Treating Patients with Recurrent Endometrial Cancer
Inclusion Criteria
- All patients must have undergone complete hysterectomy and bilateral salpingo-oophorectomy at the time of original therapy for their uterine carcinoma
- Patients must have a biopsy with histologically confirmed diagnosis of recurrent endometrial cancer confined to the pelvis and/or vagina and no evidence of extrapelvic disease
- Patients must have endometrial carcinoma including endometrioid adenocarcinoma, adenocarcinoma with squamous differentiation, mucinous adenocarcinoma, squamous cell carcinoma, mixed carcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, and serous adenocarcinoma histologies
- Patients must have no evidence of extrapelvic disease; complete workup staging should be performed prior to initiation of therapy to rule-out presence of metastatic disease; this should include: computed tomography (CT) scan of the thorax with IV contrast, as well as a CT of the pelvis and abdomen with IV and oral (PO) contrast performed using multi-detector CT and equal or less than 5 mm slice thickness; if the patient is unable to tolerate contrast, then magnetic resonance imaging (MRI) with IV gadolinium should be performed; a chest x-ray should be done first, and if abnormal, then a CT scan of the chest should be done
- Primary surgical debulking before protocol therapy is permissible; this would include removal of gross symptomatic disease in the pelvis and/or vagina * Exenterative surgery is not permissible; patients with complete resection of gross recurrent disease are eligible
- Patients may have received prior hormone therapy and/or systemic chemotherapy; such therapy must have been completed at least 6 months prior to study entry and the patient has clear evidence of disease subsequent to such therapy; patients must not have received neoadjuvant chemotherapy for the present recurrent disease
- Patients must have Gynecologic Oncology Group (GOG) performance status 0, 1, or 2
- Patients must have an estimated survival greater or equal to 3 months
- Absolute neutrophil count (ANC) >= 1,500/mm^3 , equivalent to Common Toxicity Criteria (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 3.0) grade 1
- Platelets >= 100,000/mm^3 (CTCAE v 3.0 grade 0-1)
- Creatinine =< institutional upper limit normal (ULN), CTCAE v 3.0 grade 0; NOTE: if creatinine > ULN, creatinine clearance must be > 50 mL/min
- Bilirubin =< 1.5 x ULN (CTCAE v 3.0 grade 1)
- Serum glutamic oxaloacetic transaminase (SGOT) =< 2.5 x ULN (CTCAE v 3.0 grade 0-1)
- Alkaline phosphatase =< 2.5 x ULN (CTCAE v 3.0 grade 0-1)
- Neuropathy (sensory and motor) =< CTCAE v 3.0 grade 1
- Patients with ureteral obstruction must undergo stent or nephrostomy tube placement prior to study entry
- Patients who have met the pre-entry requirements
- Patients must have signed an approved informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization
Exclusion Criteria
- Patients with evidence of disease outside of the pelvis, including presence of positive periaortic or inguino-femoral nodes
- Patients who have received previous vaginal, pelvic, or abdominal irradiation
- Patients who received chemotherapy directed at the present recurrence
- Patients with septicemia or severe infection
- Patients who have circumstances that will not permit completion of this study or the required follow-up
- Patients with renal abnormalities, such as pelvic kidney, horseshoe kidney, or renal transplantation, that would require modification of radiation fields
- Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last five years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy
- Patients who have undergone complete surgical resection of the recurrent tumor and have no evidence of residual disease evaluable clinically and by CT or MRI imaging, following resection
- Patients who have a significant history of cardiac disease, i.e., uncontrolled hypertension, unstable angina, congestive heart failure, or uncontrolled arrhythmias within 6 months of registration
- Patients with history of active collagen vascular disease
- Patients with GOG performance grade of 3 or 4
California
Auburn
Berkeley
Burbank
Burlingame
Cameron Park
Castro Valley
Davis
La Jolla
Loma Linda
Los Angeles
Modesto
Mountain View
Novato
Orange
Palo Alto
Roseville
Sacramento
San Diego
San Francisco
Santa Cruz
Santa Rosa
Sunnyvale
Sylmar
Vacaville
Vallejo
Colorado
Aurora
Connecticut
Hartford
New Britain
Delaware
Lewes
Newark
Rehoboth Beach
Seaford
Wilmington
District of Columbia
Washington
Florida
Sarasota
Georgia
Atlanta
Augusta
Gainesville
Savannah
Idaho
Boise
Caldwell
Coeur D'Alene
Emmett
Meridian
Nampa
Post Falls
Sandpoint
Illinois
Aurora
Bloomington
Canton
Carthage
Chicago
Eureka
Evanston
Galesburg
Geneva
Hinsdale
Joliet
Kewanee
Macomb
Maywood
Moline
Monmouth
Normal
Oak Lawn
Ottawa
Pekin
Peoria
Peru
Princeton
Urbana
Warrenville
Indiana
Fort Wayne
Indianapolis
Michigan City
Mishawaka
South Bend
Iowa
Bettendorf
Cedar Rapids
Clive
Des Moines
Iowa City
Sioux City
West Des Moines
Kansas
Chanute
Dodge City
El Dorado
Fort Scott
Garden City
Great Bend
Independence
Kansas City
Kingman
Lawrence
Lenexa
Liberal
Manhattan
McPherson
Newton
Overland Park
Parsons
Pratt
Salina
Wellington
Wichita
Winfield
Kentucky
Edgewood
Lexington
Louisiana
Baton Rouge
Maine
Portland
Scarborough
Maryland
Baltimore
Elkton
Massachusetts
Burlington
Springfield
Worcester
Michigan
Adrian
Ann Arbor
Bay City
Brighton
Canton
Caro
Chelsea
Clarkston
Dearborn
Detroit
East China
Farmington Hills
Flint
Grand Blanc
Grosse Pointe Woods
Jackson
Kalamazoo
Lansing
Lapeer
Livonia
Macomb Township
Marlette
Monroe
Pontiac
Port Huron
Rochester Hills
Saginaw
Sterling Heights
Warren
West Branch
Ypsilanti
Minnesota
Burnsville
Coon Rapids
Edina
Fridley
Hutchinson
Maplewood
Minneapolis
New Ulm
Robbinsdale
Saint Louis Park
Saint Paul
Shakopee
Stillwater
Waconia
Willmar
Woodbury
Mississippi
Jackson
Pascagoula
Missouri
Bolivar
Columbia
Independence
Joplin
Kansas City
Lee's Summit
Liberty
Rolla
Saint Joseph
Saint Louis
Springfield
Montana
Anaconda
Billings
Bozeman
Butte
Great Falls
Helena
Kalispell
Missoula
Nebraska
Omaha
Nevada
Henderson
Las Vegas
New Hampshire
Dover
Lebanon
Manchester
New Jersey
Camden
Mount Holly
Neptune
Newark
Paramus
Ridgewood
Toms River
Voorhees
Westwood
New Mexico
Albuquerque
New York
Brooklyn
Lake Success
Manhasset
New Hyde Park
Rochester
Stony Brook
Syracuse
North Carolina
Charlotte
Clinton
Goldsboro
Huntersville
Jacksonville
Winston-Salem
Ohio
Akron
Beachwood
Belpre
Canton
Centerville
Chillicothe
Cincinnati
Cleveland
Columbus
Dayton
Delaware
Dublin
Grove City
Kettering
Lancaster
Mansfield
Marietta
Marion
Maumee
Mayfield Heights
Mentor
Mount Vernon
Newark
Oregon
Portsmouth
Springfield
Sylvania
Toledo
Wadsworth
West Chester
Westerville
Westlake
Zanesville
Oklahoma
Oklahoma City
Tulsa
Oregon
Baker City
Gresham
Ontario
Portland
Tualatin
Pennsylvania
Abington
Allentown
Bethlehem
Bryn Mawr
Danville
Drexel Hill
East Stroudsburg
Gettysburg
Hanover
Lewisburg
Lewistown
Paoli
Philadelphia
West Reading
Wilkes-Barre
Wynnewood
York
South Carolina
Boiling Springs
Easley
Greenville
Greer
Seneca
Spartanburg
South Dakota
Sioux Falls
Tennessee
Chattanooga
Knoxville
Texas
Dallas
Houston
Sugar Land
Utah
Salt Lake City
South Jordan
Vermont
Burlington
Washington
Vancouver
West Virginia
Morgantown
Wisconsin
Green Bay
La Crosse
Madison
Milwaukee
New Richmond
West Allis
Wyoming
Casper
Cody
Sheridan
Quebec
Montreal
PRIMARY OBJECTIVES:
I. To assess whether pelvic radiation therapy with concurrent cisplatin is more promising with respect to progression-free survival than pelvic radiation therapy alone in the treatment of recurrent uterine carcinoma limited to the pelvis and vagina.
SECONDARY OBJECTIVES:
I. To capture the sites of recurrence subsequent to treatment with pelvic radiation with or without concurrent weekly cisplatin in women with recurrent uterine carcinoma.
II. To estimate overall survival of patients with recurrent uterine carcinoma treated with pelvic radiation therapy with or without concurrent weekly cisplatin.
III. To estimate the prognostic significance of the location (central pelvis versus vagina) and size of the recurrence, in addition to the prognostic significance in the salvage setting of the histological subtype, grade, patient age, race, performance status, and the presence of lymph-vascular space involvement of the original tumor at the time of initial hysterectomy.
IV. To evaluate toxicity derived from the combined cisplatin and radiation compared with radiation alone in this patient population.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients undergo external-beam radiotherapy (EBRT) to the pelvis daily on days 1-5 for 5 weeks. After completion of EBRT, patients undergo intracavitary low-dose rate or high-dose rate brachytherapy* or low-dose rate interstitial brachytherapy*.
ARM II: Patients undergo EBRT as in Arm I and receive cisplatin intravenously (IV) over 1-2 hours on days 1, 8, 15, 22, and 29. Patients then undergo brachytherapy* as in Arm I.
NOTE: *IMRT boost is allowed for patients who are not candidates for brachytherapy. IMRT may also be used for the entire course of therapy for the treatment of the whole pelvis and/or the boost in patients not undergoing brachytherapy. In both arms, treatment continues in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every month for 3 months, 3 months for 2 years and then every 6 months for 3 years.
Trial Phase Phase II
Trial Type Treatment
Lead Organization
NRG Oncology
Principal Investigator
Jonathan Michael Feddock
- Primary ID GOG-0238
- Secondary IDs NCI-2009-00603, CDR0000550975
- Clinicaltrials.gov ID NCT00492778